This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ResMed Launches Narval™ CC Mandibular Repositioning Device In The US

SAN DIEGO, June 13, 2012 /PRNewswire/ -- ResMed Inc. (NYSE:RMD), a leading developer, manufacturer and distributor of sleep and respiratory medical equipment, announced the US launch of Narval™ CC, its state-of-the-art mandibular repositioning device. The company unveiled the product at last week's American Academy of Dental Sleep Medicine annual meeting. Building on years of market leadership in France, its country of origin, Narval CC is an innovative, effective, world-class device that offers an alternative solution to patients for snoring and obstructive sleep apnea.

(Photo: http://photos.prnewswire.com/prnh/20120613/LA24222)

(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

ResMed's introduction of Narval CC follows its acquisition of the France-based Labaratoires Narval. With the acquisition, ResMed added an additional therapy method to complement its comprehensive positive airway pressure (PAP) solutions, providing a broader offering for snoring and obstructive sleep apnea sufferers.

"Obstructive sleep apnea is a severe disease which, left untreated, can have significant long-term impacts on serious conditions including heart disease, type 2 diabetes, obesity, chronic obstructive pulmonary disease, and, as very recent research has shown, cancer," stated Michael Farrell, president, ResMed Americas.  "The gold-standard therapy for obstructive sleep apnea is PAP therapy.  However, we know that today some patients either refuse PAP treatment or fail to comply. Narval CC provides an effective alternative for those untreated patients. With the release of Narval CC, ResMed is now the only PAP company with a customized solution for noncompliant patients or patients who refuse PAP treatment, giving our customers and patients another choice in their treatment."

The Narval CC provides clinically proven treatment for snoring and OSA.(1-3) The cornerstone of the design is how it maintains the lower jaw in a forward position with a patented optimized retention of the mandible. This allows natural movement of the jaw, increasing patient comfort, and resulting in superior compliance and efficacy. Each device is custom-made to suit the complex dental anatomy of individual patients using a nimble and scalable computer-aided design and computer-aided manufacturing (CAD/CAM) process.

"Narval CC's proprietary design combined with CAD/CAM technology offers one of the lightest solutions on the market. Precision-enabled digital dentistry has arrived in the mandibular repositioning device market," said Kristie Burns, general manager, dental sleep, ResMed. "With Narval CC, we finally have a way to reach a previously untreatable patient group with a solution to help them achieve a healthy night's sleep."

About ResMedResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

(1) Vecchierini M et al. Efficacy and compliance of mandibular repositioning device in obstructive sleep apnea syndrome under a patient-driven protocol of care. Sleep Med 2008;9(7):762–769 (2) Dookun R. 18 month assessment of 54 patients referred for treatment of anti-social snoring  (AHI ≤ 30/hr) with a custom Mandibular Repositioning Device (MRD). Paper presented at the World Association of Sleep Medicine & Canadian Sleep Society Congress 2011(3) Geraads et al. First intention management of obstructive sleep apnea syndrome (OSAS) by custom-made mandibular advancement device: the medium-term results. Prospective study by the General Hospital Pneumologists College (CPHG). Rev Pneumol Clin  2010;66(5):284–292

SOURCE ResMed Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs